BC PLATFORMS

Their core work

BC PLATFORMS is a French technology SME specialising in data management platforms and software infrastructure for biomedical and clinical research, with a particular focus on cancer imaging data. Their work centres on building compliant repositories for medical imaging datasets — MRI, CT, and radiomics data — that meet regulatory requirements for clinical and research use. In EU projects they contribute the data platform layer: the infrastructure that stores, structures, and makes accessible the imaging biomarkers and AI-ready datasets that other partners analyse. This positions them at the intersection of health data engineering and AI-readiness for oncology applications.

What they specialise in

How they've shifted over time

BC PLATFORMS entered H2020 through PRIMAGE (2018) with a focus on rare paediatric cancers — neuroblastoma and DIPG — using predictive in-silico modelling and imaging biomarkers to support personalised prognosis. By 2020 their focus had broadened significantly into common adult cancers (lung, breast, colorectal, prostate) through CHAIMELEON, with an explicit shift toward AI tool deployment, radiomics pipelines, and regulatory-compliant data repositories. The trend is clear: from research-oriented predictive modelling in rare diseases toward production-ready, regulation-aware health data infrastructure for AI applications at clinical scale.

BC PLATFORMS is moving toward becoming a certified health data platform provider — the infrastructure layer between clinical imaging centres and AI developers — a role that will grow in demand as EU health data space regulations tighten.

How they like to work

BC PLATFORMS participates exclusively as a consortium partner rather than a project leader, suggesting they fill a defined technical role — likely data platform and infrastructure — within larger research consortia. With 28 unique partners across 2 projects, they operate within genuinely large, multi-stakeholder consortia typical of RIA health projects, rather than small bilateral collaborations. This pattern suggests they are comfortable as a specialist contributor within complex international teams but have not yet demonstrated consortium leadership ambition in H2020.

BC PLATFORMS has built a network of 28 unique consortium partners across 11 countries through just two projects, indicating dense, well-connected consortia in the European cancer research and health AI space. Their partnerships are concentrated in the Horizon Health pillar, likely spanning clinical hospitals, imaging centres, cancer research institutes, and AI developers.

What sets them apart

BC PLATFORMS occupies a specific and valuable niche: they are not a pure AI developer, nor a clinical research group, but the platform layer that makes imaging data usable — structured, compliant, and AI-ready. For consortium builders assembling a cancer AI project, this is often the missing piece: a technically credible SME that understands both the data engineering and the regulatory environment (GDPR, EU health data space). Based in Toulouse and operating as an SME, they bring agility that large institutions cannot, while their track record in two substantial RIA projects provides credibility.

Highlights from their portfolio

• CHAIMELEON
  The largest funded project (EUR 677,500) and the most commercially relevant — directly targeting lab-to-market transition of AI tools for cancer, with a regulatory-compliant imaging repository at its core.
• PRIMAGE
  Notable for its focus on rare paediatric brain and nervous system cancers (neuroblastoma, DIPG), combining in-silico multiscale modelling with imaging biomarkers — an unusually specialised and scientifically ambitious scope for an SME participant.